Immunoscintigraphy with radiolabeled cimzia®. (DrugBank: -)
1 diseaseID | Disease name (Link within this page) | Number of trials |
---|---|---|
46 | Malignant rheumatoid arthritis | 1 |
No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | NCT01590966 (ClinicalTrials.gov) | October 18, 2012 | 30/4/2012 | Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFa in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis | Scintigraphic Detection of the Biodistribution of Tumor Necrosis Factor With a Radiolabeled Anti-TNFa in Patients With Active Rheumatoid Arthritis and Active Axial and Peripheral Spondyloarthritis | Axial and Peripheral Spondyloarthritis;Rheumatoid Arthritis | Drug: administration of Cimzia®;Drug: Immunoscintigraphy with radiolabeled Cimzia®. | University Hospital, Ghent | UCB Pharma SA | Completed | 18 Years | 70 Years | All | 41 | Phase 3 | Belgium |